Advances in Statistical Approaches to Oncology Drug Development by Ivanova, Anastasia et al.
Advances in Statistical Approaches Oncology Drug 
Development
Anastasia Ivanova, PhD [Associate Professor],
Department of Biostatistics, University of North Carolina at Chapel Hill, NC, USA
Gary L. Rosner, ScD [Professor],
Oncology Biostatistics & Bioinformatics, Sidney Kimmel Comprehensive Cancer Center at Johns 
Hopkins, Baltimore, MD, USA
Olga Marchenko, PhD [Vice President],
CSDD, Innovation, Quintiles, Durham, NC, USA
Tom Parke, BSc [Head of Clinical Trial Solutions],
Tessella, Abingdon, Oxfordshire, England
Inna Perevozskaya, PhD [Senior Director], and
Statistical Research and Consulting Center, Pfizer, Inc., Collegeville, PA, USA
Yanping Wang, PhD [Research Advisor]
Biometrics and Advanced Analytics, Eli Lilly and Company, Indianapolis, IN, USA
Abstract
We describe some recent developments in statistical methodology and practice in oncology drug 
development from an academic and an industry perspective. Many adaptive designs were 
pioneered in oncology, and oncology is still at the forefront of novel methods to enable better and 
faster Go/No-Go decision making while controlling the cost.
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Introduction
Oncology drug development is quite different from drug development in other therapeutic 
areas. Phase I oncology trials enroll actual patients rather than healthy volunteers. As a 
result, investigators and patients are more accepting of toxicity or adverse events, and the 
nature of toxicity is dose-dependent for most oncology agents. The main objective of phase I 
is to find the maximum tolerated dose (MTD) as efficiently and safely as possible. Phase I 
trials are small, with cohorts of patients evaluated at different doses until dose-limiting 
toxicities (DLTs) are reached. The main objective of phase II is to evaluate the anti-cancer 
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activity of a drug and provide further safety evaluation. Phase II trials are generally non-
randomized one-arm studies in which patients receive the dose determined in previous phase 
I studies, namely, the MTD in the US and one dose below the MTD in Europe and Japan. 
Traditionally, phase III has been the first randomized controlled study. Phase III clinical 
trials are large and complex trials that focused on being the definitive assessment how 
effective and safe a drug is compared to a current gold standard treatment. One positive 
phase III trial is generally sufficient for drug approval in most oncology indications. Despite 
being expensive, the failure rate of phase III trials in oncology drug development is high. 
There is an unmet need in pharmaceutical industry for better, more efficient designs that 
could enable better and faster decision making while controlling the cost.
In this paper we describe some recent developments in statistical methodology and practice 
in oncology drug development from an academic and an industry perspective.
Novel Methods in Phase I Trials in Oncology
The traditional or 3+3 design (1) has been widely used in oncology phase I trials. More 
efficient alternatives have been proposed, the continual reassessment method (2) (CRM) 
being one example, but most of the investigators prefer to use the 3+3 design because it is 
simple to implement. A number of challenging problems in dose-finding have appeared 
recently where the use of the 3+3 design results in a very long or very inefficient trial or 
where it simply cannot be used. These problems include trials with delayed outcomes, 
studies of drug combinations, dose-finding based on toxicity scores, and dose-finding 
methods for cytostatic agents. We review some of these methods below.
Model-Based Designs for Phase I
Several model-based designs have appeared in the literature. Unlike the 3+3 design, these 
model-based designs base dose-escalation strategies on the accruing data through parameter 
estimation. One of the most used among such design is the CRM (2). The overall goal of a 
CRM procedure for dose escalation is to find the MTD as efficiently and safely as possible. 
The original CRM proposal used a simple parametric model to characterize the relationship 
between dose and the risk of a pre-defined dose-limiting toxicity (DLT). One then uses prior 
distributions on model parameters and results from patients treated in the current study to 
update the parameters and, thereby, the estimated relationship of dose to DLT risk.
In response to some criticisms, modified versions of the CRM appeared. Current versions 
run more or less as follows. The study investigators pick a target level of risk of DLT. This 
target, often around 30%, will reflect the investigators' subjective assessment of the 
therapeutic window of the treatment. In other words, the goal is to find thedose or dose level 
that is associated with the target risk of DLTs. This dose or dose level is sometimes called 
the MTD or the recommended phase II dose (RP2D). Traditionally, anticancer drugs have 
had a narrow dose range within which one might feel that the chance of benefit might offset 
the risk of serious or severe toxicity. Under these assumptions, a target risk of 20% to 33% 
may make sense.
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After choosing a target risk, the investigators need to consider and set the dose levels to 
evaluate in the study. We use the term dose level as a generic term that includes doses of 
single agents or different dose combinations. Generally, the phase I protocols include 
specific discrete dose levels, although one may instead wish to consider a range and allow 
evaluation of any dose within this range. The latter approach will generally require a 
parametric model. An additional design requirement is the number of patients to treat at a 
given dose or dose level before deciding to escalate the dose for the next cohort. Typically, 
cohorts will consist of one to three patients.
Finally, the protocol needs a rule to indicate when to stop the study. One possibility is to 
stop when one has treated a pre-specified number of patients at a given dose level and the 
algorithm would assign that same dose to the next patient. For example, one may want to 
stop the study if one has treated six patients at dose level x and, based on all available data, 
the risk of DLT at dose level x is closer to the target than it is for any other dose level under 
evaluation, so the next patient would receive dose level x. This dose level would be the 
MTD or RP2D.
Babb, Rogatko, and Zacks (3) proposed a dose-escalation algorithm that, like the CRM, 
seeks to reach the MTD quickly but penalizes doses with predicted DLT risks above some 
threshold. This approach differs from the CRM as the CRM uses a penalty for each dose 
level based on the distance of its associated DLT risk from the target, regardless of whether 
it is above or below the target. Babb et al. called their algorithm EWOC for escalation with 
overdose control.
Newer agents, rather than attacking any cell that is dividing, say, have intracellular targets 
that appear associated with specific cancers. These targets may be altered signaling 
pathways or the state of methylation of genes in the cancer cells. While not free of untoward 
side effects, these newer agents have a very different toxicity profile than the earlier 
cytotoxic agents (4). A dose-finding trial for these agents can be based on a biomarker of an 
efficacy outcome that is often continuous (5), or both efficacy and toxicity can be used to 
determine the best dose (6). If outcome is binary dose-escalation schemes like the CRM are 
still useful.
Trials with Delayed Outcome
Dose limiting toxicity in phase I trials in solid tumors is often defined based on one cycle of 
therapy that usually lasts 3-4 weeks. In hematology oncology trials, follow-up for toxicity is 
usually 4-6 weeks. Another setting where long term toxicities are likely is radiation therapy 
trials. A number of methods have appeared for such trials that use information from all 
patients, not only patients who have completed follow-up. Cheung and Chappell (7) 
proposed a time-to-event modification of the CRM (2), called TITE-CRM. Ivanova et al. (8) 
proposed a similar frequentist method. The method of Bekele et al. (9) also uses partial 
information from patients to estimate the dose-toxicity relationship. Additionally, it 
prescribes if the next patient can be enrolled right away or if more time is needed to collect 
follow-up data on already enrolled patients. The method of Ivanova et al. (8) and its 
variations have been used in a number of trials at the Lineberger Comprehensive Cancer 
Center (LCCC) (10).
Ivanova et al. Page 3
Ther Innov Regul Sci. Author manuscript; available in PMC 2015 May 04.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Dose-finding with Multiple Agents
It is common in oncology to treat patients with drug combinations. A method in Thall et al. 
(11) was one of the first dose-finding methods for drug combinations and has the ambitious 
goal of finding the whole contour of maximum tolerated drug combinations. The method is 
based on parametric functions that characterize each single agent's dose-DLT relationship 
and a model for the interaction. Other methods have a goal of finding several maximum 
tolerated drug-combinations, one for each dose of one of the agents (12,13), or a single 
maximum tolerated combination by searching over a grid of possible combinations 
(14,15,16). Though a number of methods have been developed for finding at least one 
maximum tolerated combination, nevertheless the method of choice to date has been to 
specify the sequence of drug combinations such that the MTD rate is monotonically 
increasing and use a single dimensional method, such as the 3+3 design or the CRM (2), to 
find the MTD.
Dose-finding Based on Toxicity Score
Toxicity in oncology is measured on a scale from 0 to 5. The DLT is typically defined as 
study drug related non-hematological toxicity of grade 3 or higher or study drug related 
hematological toxicity of grade 4 or higher. Bekele and Thall (17) used a sophisticated 
weighting system and ordinal toxicity variables with up to four categories. They proposed a 
Bayesian design for such trials. Some authors extended this idea and proposed to define a 
measure of toxicity called the toxicity index. The MTD is then defined as the dose with the 
toxicity index equal to a certain value (18,19). We are not aware of trials that used complex 
toxicity scoring. Our examples, two trials conducted at the LCCC (20,21), used a simpler 
approach where the MTD was defined based on DLT rate as well as on the rate of dose 
reductions. At the request of the investigators a rather simple method similar to the 3+3 
design was used for assignment (22). Dose reduction rate was included in the definition of 
the MTD because the investigators did not want to recommend a dose that is likely to be 
reduced later in a cycle. The outcome of each patient was classified as DLT or toxicity that 
was not a DLT but caused a dose reduction or no toxicity. Since DLTs are more detrimental, 
they were scored twice as much compared to toxicities that cause dose reductions. The MTD 
was defined as the dose where
Safety Monitoring for Expansion Cohorts
Commonly, phase I studies in cancer include expansion cohorts. These are groups of 
patients who receive the putative recommended phase II dose or MTD after the dose 
escalation part of the study has determined the recommended dose. The goal of treating this 
group of patients may be to evaluate the drug in more patients and estimate the risk more 
precisely, to examine differences between men and women, or to get preliminary efficacy 
information. As long as the patients enrolled in the expansion cohort are roughly similar to 
the patients who participated in the dose-escalation part of the study (i.e., the expansion 
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patients satisfy the same eligibility criteria), it is reasonable to consider the information from 
the prior patients to apply to the expansion cohort.
Of particular relevance for the expansion cohort is the safety information from the dose-
escalation part of the study. Since patients in this cohort will receive the MTD determined 
earlier in the study, one has preliminary information about the risk of a DLT. One can use 
this preliminary information as a basis for safety monitoring rules for the expansion cohort. 
For example, we might consider that six patients received the MTD prior to starting the 
expansion phase. Assuming a uniform prior (i.e., beta(1,1)) for the risk of DLT, one DLT 
out of six patients leads to a beta(2, 6) posterior probability distribution for the risk of DLT. 
If the target risk of DLT during dose escalation was 30%, then a reasonable safety 
monitoring rule would stop treating patients if it appears that the risk is higher than that 
target. Following this logic, one might want to stop treating patients if the posterior 
probability is 75% or more (i.e., 3:1 odds or more) that the risk of DLT is 0.3 or higher. This 
probability is easy to compute, since the posterior probability follows a beta distribution, and 
most statistical software packages have functions for evaluating probabilities for a beta 
distribution.
Phase II Methods in Oncology Trials
Review of Methods for Phase II Trials in Oncology
The general purpose of phase II studies in oncology is to get an early indication of activity 
of the treatment. In the past, the primary endpoint in oncology was related to tumor 
shrinkage. That is, if the treatment would lead to reduction in the size of the tumor within a 
short period of treatment, then the treatment might provide long-term benefit. Ultimately, 
the goal is to extend life, and tumor shrinkage is an early sign that the treatment might help 
eradicate disease. Unfortunately, tumor shrinkage does not always correlate with extended 
survival, and newer targeted agents may slow tumor growth—at least initially—rather than 
shrink tumors within a couple of months. As a result of these considerations, especially in 
the era of evaluating agents that target specific molecular pathways thought to be involved 
in cancer growth, many phase II studies use other endpoints than tumor shrinkage. For 
example, delaying disease progression may indicate drug activity, so the primary endpoint 
may be the probability of being alive and free of progression (i.e., progression-free survival) 
at some specific time after starting treatment, such as six months. Mick et al. (23) consider 
the ratio of the current time to progression to the patient's previous time to progression as a 
measure of benefit. Rosner et al. (24) propose the use of randomized discontinuation designs 
when tumor growth rates exhibit heterogeneity and the proposed treatment may slow or stop 
tumor growth but not shrink the tumors immediately.
Many patients, including some with metastatic disease, experience slow growth of their 
tumors. Heterogeneity in tumor growth across patients may make it difficult to tell if longer 
than expected times-to-progression are a result of the treatment or disease heterogeneity. 
Thus, phase II studies with progression-free survival as the primary endpoint should be 
randomized. A subcommittee of the U.S. National Cancer Institute has proposed guidelines 
for phase II study designs in oncology, in an effort to improve the state of the science (25). 
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These guidelines focus on phase II endpoints and reflect the committee's opinions regarding 
endpoint-appropriate designs.
Most of the oncology phase II trials are single arm and use either Simon's two stage design 
(26) or Gehan's design (27). Evidence shows (28) that, in recent years, Simon's design is the 
most frequently used design for phase II trials. Simon's design is a two-stage design with the 
possibility to stop for futility after stage one. Usually the design that yields the minimum 
total sample size, the minimax design, or the design that yields the smallest sample size 
under the null hypothesis, the optimal design, is used. Jung et al. (29) recommended 
considering not only the minimax and the optimal design, but all designs that minimize the 
weighted average of the total sample size and the expected sample size under the null 
hypothesis. This method yields a number of useful designs for an investigator to choose 
from, in particular, they offer a wider selection of stage one sample sizes. Other extensions 
of Simon's design include the three stage design (30), the Fleming's two-stage design (31) 
that allows stopping for either efficacy and futility, the two-stage design with ordinal 
outcomes (32, 33), and a two-stage design with two arms (34). Table 1 displays various 
extensions of the Simon's two-stage design that have been proposed for phase II oncology 
trials.
Two-stage Design with Ordinal Outcomes
As the goal of a phase II trial is to quickly screen new agents, the concept of looking at 
several outcomes at the same time is very appealing. Some investigators proposed looking at 
complete and partial responses (32), some proposed looking at tumor response and disease 
control (33) (defined as tumor response or stable disease), some at tumor response (or 
disease control) and progression free survival (35, 36). The treatment is considered 
promising if it improves at least one of the outcomes. To give more details, let pT and pD, pT 
≤ pD, denote the probability of tumor response and disease control in the population, 
respectively, and p0T and p0D, p0T ≤ p0D, denote the null probabilities of tumor response and 
disease control. Define the two null hypothesis H0T: pT ≤ p0T versus H1T: pT > p0T, and H0D: 
pD ≤ p0D versus H1D: pD > p0D. Consider testing the intersection of these two hypothesis:
The treatment is considered promising if either tumor response rate or disease control rate is 
promising. The treatment is not considered promising if both tumor response and disease 
control rates are low. Lu et al. (32) and Ivanova et al. (33) describe how to construct Simon-
like two-stage designs for testing two components of the ordinal outcome, e.g. tumor 
response and disease control. Zee et al. (35) and Sun et al. (36) describe how to test a binary 
endpoint and a survival endpoint simultaneously in a two-stage trial.
Stopping Rules for Phase II Trials
While the purpose of phase II studies is to determine if the treatment has some activity 
against the disease, there may not be a lot of experience treating patients with the therapy. 
Thus, monitoring the phase II patients for safety is often appropriate. Monitoring toxicity on 
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a continuous basis, that is, being able to stop the study at any point, provides the best 
protection against observing an excessive number of toxicities and therefore is preferable to 
multi-stage stopping rules. Ivanova, Qaqish, Schell (37) illustrated that the Pocock-type (38) 
stopping boundary allows stopping the trial as early as possible, if the toxicity rate is high, 
and therefore prevents treating too many patients on a regimen that is not safe.
Geller et al. (39) proposed a Bayesian continuous stopping rule for phase II trials. Bayesian 
stopping rules for toxicity monitoring in phase II are similar to the Bayesian monitoring 
rules discussed earlier in the section relating to phase I studies. These rules would call for 
stopping the treatment if more patients are experiencing serious adverse events than one 
might have anticipated before starting the study. Of course, the procedure we discussed in 
the phase I section assumed that one has reduced the safety outcome to a simple yes or no 
event and that one has a target risk one does not want to exceed. For example, one might 
assume, based on earlier phase I studies, that the risk of serious adverse events is around 
30%. Since phase I studies typically treat relatively few patients, there is likely uncertainty 
about the true risk. One might characterize this uncertainty with a prior distribution for the 
risk, such as a beta(6, 14) distribution. This prior corresponds to a mean risk of serious 
adverse events of 30%, with 90% probability that the risk is between 15% and 48%. If one 
has greater certainty about the risk, one should use a different prior distribution. The next 
step is to decide on the level of certainty that one requires to stop treating future patients. 
For example, one might want to be at least 80% certain that the risk of a serious adverse 
event is greater than 30%, corresponding to 4:1 odds. Often, the protocol will contain tables 
that illustrate the stopping rules and the average behavior of the rules under different 
scenarios corresponding to different underlying “true” risks. The final rules should reflect 
the concerns and judgment of the clinical investigators and the statisticians.
Phase II Trials with Two Arms
Kepner (34) described how to compute two-stage designs with the possibility of stopping for 
efficacy and/or futility after stage one when the outcome is binary. As it is time consuming 
to search for all possible designs, Kepner (34) proposed to search for designs with the first 
stage sample size that is the closest to one half of the total sample size.
Bayesian Phase II Designs
Phase II designs have typically been based on a frequentist, hypothesis-testing framework. 
For example, the Simon two-stage design seeks to minimize the sample size under the null 
hypothesis while achieving pre-specified size under the null and power to detect some 
alternative hypothesis. Several investigators have proposed phase II designs that rely on 
Bayesian computation. Cook and Johnson (40) proposed designs for comparing two 
hypotheses but from a Bayesian perspective. They use the Bayes factor, a measure of the 
strength of evidence in the data in favor of one hypothesis over another, for comparing the 
two hypotheses of interest. They develop this procedure using prior distributions based on 
alternatives that yield efficient designs.
Other designs in the literature consider stopping the study when there is high posterior 
probability that a key parameter, such as the probability of tumor shrinkage, exceeds a pre-
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specified threshold. For example, Thall and Simon (41) propose a single-arm design that sets 
up decision rules based on posterior probabilities relating a new treatment to the assumed 
efficacy of a current standard treatment. Aside from attaching uncertainty to the measure of 
efficacy (e.g., response probability) of the experimental treatment, they also allow for 
uncertainty about the efficacy of the standard. Even though patients in the study only receive 
the new treatment and no new information regarding the current standard will arise from the 
study, accounting for uncertainty about the standard's efficacy via a prior distribution adds 
more variation and improves the frequentist characteristics of the design. Tan and Machin 
(42) describe a two-stage design that uses posterior probabilities to decide whether to 
proceed from the first stage to the second. Sambucini (43) modifies the Tan and Machin 
design to use predictive probabilities rather than posterior probabilities. By using predictive 
probabilities, the design accounts for variation in future observations. Furthermore, 
Sambucini considers a range of alternatives, via a design prior, rather than fixing the “true” 
underlying response probability at a single point.
Lee and Liu (44) proposed a related procedure that also bases decisions on predictive 
probabilities, rather than posterior probabilities. Their design will ensure control of Type I 
and Type II error probabilities. Furthermore, unlike the Tan and Machin approach, Lee and 
Liu's proposal allows one to monitor the study as often as one needs. Continual monitoring 
has the potential to lead to smaller expected sample sizes under the null hypothesis, 
compared to a design with just one or two interim futility analyses.
Confirmatory Oncology Trials
Traditionally, phase III in oncology drug development has been the first randomized 
controlled study phase. Some of the reasons for this phenomenon include the dose-
dependent nature of toxicity for most oncology agents, the acceptance of toxic treatments by 
oncologists and by patients, and belief that small trials with an observed response rate as a 
primary endpoint have sufficient information to guide further development of a clinical 
program. Insufficient exploration of safety and efficacy of cancer drugs in early phases of 
development together with the complex life-threatening nature of the disease has led 
oncology drug development to have a high rate of failure in confirmatory trials (45). In order 
to compensate for some oncology development shortcuts, to improve the chance of a 
success, and to expedite time-to-market, some phase III trials have been employing designs 
with adaptive features such as the possibility to stop early for futility or efficacy, sample size 
re-estimation, implementation of enrichment strategies, etc. Stopping for efficacy during an 
interim analysis is not commonly considered because the full sample size is usually required 
in order to satisfy regulatory requirements for the adequacy of the safety database in the 
overall development program. But if the treatment effect is very strong, ethical 
considerations may warrant early termination of the study (46). Bretz et al. give a nice 
overview of adaptive designs used in confirmatory clinical trials (47).
Seamless phase II/III designs have become more popular in oncology drug development 
(48,49,50,51). Such designs aim to reduce the overall sample size by allowing the data from 
phase II patients to be used in phase III analysis (inferentially seamless) (48,49) or/and 
eliminating the time between phases, which results in a shorter total drug development time 
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(operationally seamless). Just as there are a number of phase II designs, there are a number 
of corresponding phase II/III designs. More on different seamless designs in oncology and 
design efficiency in phase II/III trials can be found in Korn et al (52).
Available Software
MD Anderson Comprehensive Cancer Center provides a site with software to implement a 
number of designs for oncology trials: https://biostatistics.mdanderson.org/
SoftwareDownload/. All admissible Simon's (26) and Fleming's (31) designs can be 
generated using the software available at the Lineberger Comprehensive Cancer Center site 
at http://cancer.unc.edu/biostatistics/program/ivanova/. This software can also generate the 
two-stage designs with ordinal outcome (33) and the Pocock boundary for continuous 
toxicity monitoring in a single arm phase II study (37). Two-stage, two-arm study designs 
for binary outcomes can be generated using software at www.cryptnet.net/kepner.
Discussion
Oncology drug development has been a tremendous challenge. Cancer clinical studies are 
typically lengthy and costly; yet, the failure rate is high. For example, only 34% of phase III 
oncology trials with results reported from 2003 through 2010 were successful (45). While 
insufficient understanding of the disease (such as pathway targets) and effective candidate 
therapeutics certainly contribute to the high failure rate, it has been argued by many that 
more robust clinical development strategies need to be in place to increase the probability of 
success in oncology drug development.
In recent years, a considerable amount of scientific work has focused on early phase 
oncology development. While the “3+3” design remains the most used phase I design, 
according to a literature search by Rogatko et al. (53) and Le Tourneau et al. (54), the CRM 
design and its modifications are making their way to trials run by pharmaceutical industry 
(55,56). The 3+3 design is inefficient in establishing the dose that meets a specific target 
toxicity level and may involve an excessive number of escalation steps, leading to a large 
proportion of patients treated at sub-therapeutic doses. Additionally, the 3+3 design has a 
low probability of selecting the true MTD (57) and yields high variability in MTD estimates 
(58). Model-based methods that use all toxicity information accumulated during the trial 
achieve better estimates of the target probability of dose-limiting toxicity at the 
recommended dose without treating too many patients at sub-therapeutic doses, but 
implementation of these designs is not as simple as for the 3+3 design. There is a need for 
upfront planning, expedited collection of data from each patient or cohort to fit the model, 
biostatistics expertise, and software to perform model fitting in real time. Following the 
considerable amount of criticism received by the original version of the CRM, the algorithm 
has since been substantially modified and refined, both in its theoretical development and in 
its practical implementation. Seamless designs including phase I/II (mostly operationally 
seamless) have become more popular in the pharmaceutical industry. The first part (phase I) 
uses a model-based design to find the MTD, and the second part (phase II) treats a cohort of 
additional patients at the MTD to evaluate efficacy and further study safety in the same 
population or in a particular indication proposed for further development. The setting is 
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similar to safety monitoring for expansion cohorts. Drug combination studies are common in 
oncology and require special consideration for identifying an optimal dose combination. 
Phase I trials with drugs expected to produce delayed or cumulative toxicities should 
incorporate specific dose-finding methods and account for delayed or cumulative toxicities.
A paradigm shift in the past decade from traditional cytotoxic agents to molecular targeted 
therapies (from drugs primarily targeting DNA to those primarily targeting cellular 
signaling) has occurred. Given the different mechanisms and toxicities of these agents, drug 
development methodology may need to change. The Task Force on Methodology for the 
Development of Innovative Cancer Therapies (MDICT) was appointed by the NDDO 
Research Foundation (www.nddo.org) for the purpose of addressing methodological issues 
created by this shift. The MDICT published its recommendations on Phase I and II studies 
of targeted anticancer therapy but has not provided guidance on statistical methods specific 
for molecularly targeted compounds, acknowledging that “toxicity remains the most 
commonly used information upon which decisions are made for the recommended Phase II 
dose of targeted agents” (59,60). The phase II study design is a critical component of the 
clinical development strategy and has been one of the focal points in recent literature of 
oncology clinical development strategy. In this article, we reviewed some of the recent 
developments in Phase II study designs in oncology. Traditionally, single-arm study designs 
have been the mainstream in phase II oncology development, but because of patient 
selection and other biases associated with single-arm studies there has been a gradual shift to 
randomized designs for phase II. Yet, for certain mono-therapy trials with tumor response 
rate as the primary endpoint, single-arm designs are still acceptable (25). For single-arm 
studies, Simon's two-stage design and its various extensions have been commonly used due 
to its simplicity and its built-in mechanism to stop early due to futility. Assuming the same 
Type I and II errors, the design is optimal in the sense of minimizing the expected sample 
size under the null hypothesis. In practice, however, to achieve the optimal expected sample 
size, the sponsor will need to put the enrollment on hold after the first stage patients are 
enrolled until their data are available for analysis. One approach to avoid halting enrollment 
with a two-stage design was given by Herndon (61).
Because of the inherent drawbacks of single-arm designs, randomized designs are now being 
increasingly used in phase II oncology development, particularly when a time-to-event 
outcome, such as progression-free survival, is the primary endpoint. Randomized designs 
offer more objective and robust comparisons between experimental and control regimens, 
thus enabling better commercial decision making (so called Go/No-Go decision making). 
The price, however, is that the size of phase II may be much larger than single-arm studies 
to achieve reasonable study power, which could be a challenge for the “speed to market” 
strategy pursued by many sponsors in the increasingly competitive oncology market. On the 
other hand, there are rich historical data on the control regimen in many situations that could 
and should be leveraged when designing randomized phase II studies. Bayesian methods 
that incorporate historical control data into randomized studies have been proposed in phase 
II oncology development (62). In phase II development, there remains a huge unmet need 
for better, more efficient designs that could enable better and faster Go/No-Go decision 
making while controlling the cost. Some have advanced the idea of incorporating decision 
theory into the design of phase II studies of cancer therapies (63,64). Potential areas for 
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research include better, faster, and cheaper surrogate endpoints for survival, treatment-
selection biomarkers that predicts a large treatment effect, etc.
While adaptive designs have become more popular in every stage of drug development, 
phase III designs are more conservative, given the regulatory requirements for confirmatory 
trials. Seamless phase II/III trials are getting some recognition and gaining popularity in 
oncology drug development. Because the regulatory issues are similar for seamless phase 
II/III trials as for phase III adaptive trials, the FDA guidance does not distinguish them. 
While regulators suggest limiting the use of adaptive designs at the confirmatory stage, they 
encourage further exploration of new methods, including adaptive designs in early phase of 
drug and biologic development (46).
Heterogeneity of disease is a widely acknowledged problem in cancer, and very difficult to 
address in the course of a clinical trial. It is the “next big problem” that oncology trial design 
has to tackle; perhaps designs used in BATTLE (65), I-SPY 1 (66), and I-SPY 2 (67) trials 
(www.ispy2.org) that pair oncology therapies and biomarkers point the way. Many newer 
designs, while superior in some ways to currently used designs, do not find their way into 
common usage right away. There are various reasons, including the need for specialized 
software, difficulty for non-statisticians to understand the methods, and reluctance on the 
part of government agencies to accept novel designs. In this paper, we have presented many 
new innovations in the design of clinical studies to hasten their acceptance and adoption.
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Table 1
Extensions of the Simon's two-stage design for phase II oncology trials
Simon's two stage design Extensions of the Simon's design
Two-stage Three-stage (30)
Stopping for futility only Stopping for futility and efficacy (31)
Binary endpoint Ordinal outcome (32, 33)
Minimax or optimal All admissible designs (29)
Single arm Two-arm (34)
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